Research Summary

I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

Research Funding

  • January 4, 2021 - January 3, 2024 - Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy, Principal Investigator. Sponsor: Prostate Cancer Foundation, Sponsor Award ID: 20YOUN07
  • January 4, 2021 - January 3, 2024 - Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy, Principal Investigator. Sponsor: Prostate Cancer Foundation, Sponsor Award ID: 20YOUN07
  • January 4, 2021 - January 3, 2024 - Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy, Principal Investigator. Sponsor: Prostate Cancer Foundation, Sponsor Award ID: 20YOUN07
  • January 4, 2021 - January 3, 2024 - Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy, Principal Investigator. Sponsor: Prostate Cancer Foundation, Sponsor Award ID: 20YOUN07

Education

University of Pennsylvania, Philadelphia, PA, BA, 05/2007, Cognitive Science
University of Chicago, Chicago, IL, MD, 06/2012, Medicine
University of Michigan Health System, Ann Arbor, MI, Intern, 06/2013, Internal Medicine
University of Michigan Health System, Ann Arbor, MI, Resident, 06/2015, Internal Medicine
Cleveland Clinic, Cleveland, OH, Fellow, 06/2018, Hematology-Oncology

Honors & Awards

  • 2019
    Junior Clinical Investigator Award, Helen Diller Family Comprehensive Cancer Center
  • 2017
    John Quale Travel Fellowship Award, BCAN Bladder Cancer Think Tank
  • 2017
    Young Investigator Abstract Award, International Kidney Cancer Symposium
  • 2017
    Conquer Cancer Foundation Merit Award, ASCO 2017 Annual Meeting
  • 2016
    AACR/ASCO Methods in Clinical Cancer Research Workshop Participant
  • 2017
    Accelerating Anticancer Agent Development & Validation Workshop Participant
  • 2016
    FDA-ASCO: Hematology and Oncology Fellows Day Workshop Participant
  • 2015
    ASCO 2015 Annual Meeting Merit Award
  • 2011
    Teaching Assistant for Clinical Pathophysiology and Therapeutics (top 20% of med school class)
  • 2009, 2012
    Keith Edson Scholarship for International Medicine Experience
  • 2009
    Certificate of Merit Award for education exhibit at RSNA annual meeting

Selected Publications

  1. Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Ozguroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol. 2020 Sep 17.
    View on PubMed
  2. Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. J Urol. 2020 Sep 16:101097JU0000000000001371.
    View on PubMed
  3. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Invest New Drugs. 2019 Jun;37(3):559-566.
    href="https://pubmed.ncbi.nlm.nih.gov/31037562/">View on PubMed
  4. Koshkin VS, Small EJ. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Nov 11;10(12):445-454.
    View on PubMed
  5. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 Jan 1;25(1):210-221.
    View on PubMed
  6. Koshkin VS, Grivas P. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol. 2018 Jun;7(3):504-507.
    View on PubMed
  7. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest. 2018 Aug 1;128(8):3333-3340.
    View on PubMed
  8. Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018 Jun 5;14:1019-1040.
    View on PubMed
  9. Koshkin VS, Grivas P. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Curr Oncol Rep. 2018 Apr 11;20(6):48.
    View on PubMed
  10. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Target Oncol. 2018 Jun;13(3):353-361.
    View on PubMed
  11. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892.
    View on PubMed
  12. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 Jan 29;6(1):9.
    View on PubMed
  13. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017 Oct 1;28(10):2458-2463.
    View on PubMed
  14. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 Mar;5(2):242-249.
    View on PubMed
  15. Grivas P, Koshkin VS, Pal SK. Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Ann Oncol. 2017 Apr 1;28(4):680-682.
    View on PubMed
  16. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20;34(30):3680-3685.
    View on PubMed
  17. Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun;17(9):1225-32.
    View on PubMed
  18. Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH. CAD-associated reader error in CT colonography. Acad Radiol. 2012 Jul;19(7):801-10.
    View on PubMed
  19. Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, Snyder EY, McIntosh TK. Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain. Brain Res. 2005 Dec 14;1065(1-2):8-19.
    View on PubMed

Go to UCSF Profiles, powered by CTSI